Introduction {#s1}
============

An estimated 7.6 million children die globally every year before the age of five [@pmed.1001238-UNICEF1]. 99% of these deaths occur in developing countries; 50% in sub-Saharan Africa [@pmed.1001238-You1]. Most of these deaths are due to a few treatable and preventable diseases, for which effective interventions are already available [@pmed.1001238-Jones1],[@pmed.1001238-Claeson1]. Delivering these interventions is essential to achieving the 4th Millennium Development Goal (MDG), which aims to reduce the under-five mortality rate by two-thirds by 2015. In Kenya, the under-five mortality rate has to be reduced by 50% from its 2008 level to meet the MDG target. Improving case management of serious illness might help achieve this goal [@pmed.1001238-English1],[@pmed.1001238-Snow1], and we have recently described one possible approach to this in Kenyan district hospitals [@pmed.1001238-Ayieko1]. That approach included the development and implementation of evidence-based clinical practice guidelines (CPGs) linked to health worker training, follow-up supervision, performance feedback, and facilitation (for brevity referred to as the ETAT+ strategy) [@pmed.1001238-Irimu1],[@pmed.1001238-English2]. However, while the strategy was effective, would scaling up the approach be a good use of limited resources? Addressing this question demands a rigorous evaluation of costs and consequences with such data used to estimate the costs and effects of scaling up the intervention to reach the population in need. This paper presents a cost-effectiveness analysis performed alongside the previously reported cluster randomized trial of the effects of the ETAT+ strategy. We also present an assessment of the costs of scaling up the intervention to the national level and speculate on, using a simple model that assumes the strategy reduces inpatient mortality, the possible costs per disability adjusted life year (DALY) averted.

Methods {#s2}
=======

Study Design {#s2a}
------------

This was a cost-effectiveness analysis alongside a cluster randomized controlled trial (cRCT). The time horizon selected was 18 mo (September 2006--April 2008), which was the period during which the intervention was implemented and evaluated. Costing took a provider\'s perspective. While this is often considered narrow [@pmed.1001238-World1],[@pmed.1001238-Drummond1], for the purpose of this analysis, we considered it sufficient as it encompasses the relevant range of costs and effects of interest to policy makers responsible for budgeting and planning for scale-up in Kenya. To account for differential timing and time preference, we discounted costs and outcomes using a 3% annual discount rate [@pmed.1001238-Walker1]. Costs were adjusted for inflation using gross domestic product (GDP) deflators for Kenya [@pmed.1001238-World2] and are valued and presented in 2009 US\$. Effects are measured in terms of process indicators of quality of care that include important measures of child assessment, diagnosis, classification, and treatment on admission. Probabilistic sensitivity analysis using Monte Carlo simulation was used to assess the impact of uncertainty around hotel costs, development costs, medicine costs, staff salaries, and effectiveness estimates.

Data Collection and Sample Sizes {#s2b}
--------------------------------

In this cRCT (described in full elsewhere [@pmed.1001238-Ayieko1]), eight rural district hospitals in four provinces in Kenya were randomized into four full and four partial intervention hospitals, hereafter termed intervention and control hospitals [@pmed.1001238-Ayieko1]. Resource use data were collected via clinical record reviews conducted at baseline and at 6-monthly intervals over an 18-mo period (four surveys in total). During each survey, these reviews were conducted on 400 randomly selected pediatric admissions. Admissions were included if children, aged between 2 and 59 mo, were admitted for acute illnesses during the preceding 6-mo time period. The total sample included 6,199 and 5,115 record reviews of pediatric admissions for intervention and control hospitals, respectively. The clinical performance indicators used as the measure of effectiveness in this analysis were extracted from 1,158 and 1,157 records at 18 mo post implementation in the intervention and control hospitals, respectively.

The Intervention {#s2c}
----------------

The intervention was a package of care intervention that was delivered in the form of evidence-based CPG dissemination [@pmed.1001238-Irimu1], health worker training, job aids, follow-up supervision, and local (health facility) facilitation by a nurse or diploma level clinician [@pmed.1001238-Ayieko1],[@pmed.1001238-English2]. The role of the local facilitator was to offer local oversight and on-site problem solving to support facilities implementing the intervention. The training course was developed from the existing World Health Organization (WHO) Emergency Triage, Assessment and Treatment (ETAT) course with the addition of new materials on newborn resuscitation and case management of common causes of serious illness in the newborn or child and with the CPGs spanned: emergency pediatric care, malaria, pneumonia, asthma, diarrhea and dehydration, meningitis, malnutrition, and neonatal care [@pmed.1001238-Irimu1]. This new training was therefore given the name "Emergency Triage Assessment and Treatment Plus Admission Care (ETAT+)."

In intervention hospitals, the intervention was delivered over 18 mo as a combination of ETAT+ training for health care workers conducted over 5.5 d, dissemination of CPG booklets, job aids, and pediatric admission record (PAR) forms [@pmed.1001238-Ayieko1]. The PAR is a structured form used by clinicians to document key symptoms and signs of a sick child\'s clinical information on admission [@pmed.1001238-Mwakyusa1]. This was followed by 2--3-monthly supervisory visits that sometimes included short, ad hoc follow-up training and appointment of a local facilitator in each facility linked to hospital supervisors by regular phone calls from the study team [@pmed.1001238-English2],[@pmed.1001238-Nzinga1]. Results and feedback reports of the surveys conducted in the facilities were disseminated in face-to-face meetings in intervention hospitals.

In the control hospitals, a partial version of the intervention was delivered in the form of CPG booklet distribution, a 1.5-d seminar, and provision of written survey feedback based on written reports only. Control hospitals did not receive any follow-up supervisory support or local facilitation.

Evaluating Effectiveness {#s2d}
------------------------

We used process indicators of quality of care to estimate the effectiveness of the intervention. In total 14 pre-specified indicators that span three broad areas were considered as primary outcomes [@pmed.1001238-Ayieko1]: assessment of a severely ill child, therapeutic care, and supportive care on admission. These indicators cover the diseases (malaria, pneumonia, and diarrhea/dehydration) that result in 60% of inpatient deaths in children under five in Kenya. Effectiveness was then estimated as the between-group (intervention and control) difference using logistic or linear regression analyses for each of the 14 process measures while adjusting for hospital-level covariates (all-cause pediatric mortality, malaria transmission, and hospital size). This procedure is described in detail elsewhere [@pmed.1001238-Ayieko1]. Further details of the effectiveness analysis are also provided in [Figure S1](#pmed.1001238.s001){ref-type="supplementary-material"}.

Evaluating Costs {#s2e}
----------------

Costs were categorized as intervention development, intervention implementation, and inpatient pediatric treatment costs. The latter were included in order to capture any change in resource use associated with the implementation of best practice pediatric care. Costs were summed across all categories to obtain the total cost per hospital and per hospital admission in intervention and control hospitals. Each cost category is further described in the following sections. Costs were collected using clinical and accounting record reviews and interviews with those involved in developing and implementing the intervention.

Guideline Development Costs {#s2f}
---------------------------

Development costs included the staff costs incurred in the development of ETAT+ guidelines and training, the costs of course training materials, and costs of organizing and running meetings and workshops. Staff costs were calculated by interviewing key staff involved in guideline development in order to estimate the amount of time spent on these activities. The opportunity cost of this time was then assumed to be equivalent to the associated cost of employment. The costs of course training materials were assumed to be equivalent to the market prices of these items. Development costs were annualized over 4 y, which was assumed to be the useful life of the clinical guidelines.

Guideline Implementation Costs {#s2g}
------------------------------

Implementation costs included the costs of initial ETAT+ training of health workers, follow-up training, supervisory visits and phone calls, feedback meetings, and on-site local facilitator costs. The opportunity costs of resources used in these activities, e.g., staff time used in attending trainings, were evaluated by estimating the number of days spent at each training workshop and calculating the costs on the basis of the equivalent cost of employment. The costs of the initial training were considered to be capital costs as the effects of the training were expected to be realized over a period of more than 1 y. These costs were annualized over a useful life of 2.5 y, which was the length of time over which the practice change effects were seen to be sustained [@pmed.1001238-Ayieko1]. Follow-up activities and supervision were considered to be recurrent costs.

Treatment Costs {#s2h}
---------------

Treatment costs were computed as the sum of "hotel," medicine, and laboratory costs per admission. Resource use data for patient length of stay in hospital, medicines, and laboratory tests were collected from patient clinical records. Estimates of the utilization of these resources were then multiplied against the unit cost of each item. Per diem "hotel" unit costs were derived from the WHO, "Choosing Interventions that are Cost Effective" (WHO-CHOICE) estimates and recent work on the economic costs of inpatient care in Kenya [@pmed.1001238-Ayieko2],[@pmed.1001238-World3]. Medicine unit costs were derived from 2009 market prices while unit costs of diagnostic tests were based on non-profit cost recovery prices from a Kenyan district hospital [@pmed.1001238-Ayieko2]. Given the skewed nature of cost data, treatment costs are presented as both means (with confidence intervals) and medians (with interquartile ranges).

Evaluating Cost Effectiveness {#s2i}
-----------------------------

The cost-effectiveness analysis compared the implementation of the ETAT+ strategy as delivered in the intervention hospitals with the partial intervention as delivered in the control hospitals. The partial intervention was chosen as a comparator because it mirrors practice that would be considered a basic, standard approach to dissemination of guidelines that does not typically include active follow-up or supervision and for ethical reasons (withholding new national guidelines was deemed unreasonable). While "no intervention" is an alternative counterfactual, this assumes, somewhat unrealistically to us, that no national or international body will produce guidelines or disseminate them or make attempts to improve poor hospital services.

The summary measure of effect was the mean of the adjusted differences between control and intervention hospitals at 18 mo. This was calculated as the mean percentage improvement in the 14 process of care indicators in intervention compared to control hospitals (Equation 1), with 95% CIs obtained by bootstrapping with 2000 iterations.Where: *Q*, mean percentage improvement in process of care; *Ei*, adjusted difference of each process of care between control and intervention hospitals at 18 mo; *n*, number of processes of care.

Assessing Cost Effectiveness {#s2j}
----------------------------

The incremental cost-effectiveness ratio (ICER) was defined as the incremental cost per percentage gain in mean quality based on the 14 indicators. This is the ratio of the difference in the total admission cost per child between intervention and control hospitals, and the difference in mean quality improvement (Equation 2).Where: *C* ~i~, *c*hild admission costs in intervention hospitals; *C~c~*, *c*hild admission costs in control hospitals; *E* ~i~, percentage improvement in process measures of quality in intervention hospital; *E~c~*, percentage improvement in process measures of quality in control hospitals.

The cRCT was not designed to examine effects on health outcomes, therefore we explored the potential incremental cost per DALY averted on the basis of conservative assumptions of the effect of improving quality of care on inpatient childhood mortality. We assumed relative reductions in the mortality rate of between 1% and 10%, equivalent to absolute reductions of between 0.07% and 0.7% with median inpatient mortality, derived from the eight hospitals, equal to 7%. The proportion of lives saved from the respective diseases (malaria, pneumonia, and diarrhea) were assumed to be equivalent to the proportions of the contribution of each of these diseases to under-five childhood deaths in Kenya [@pmed.1001238-Black1]. In this "what-if" analysis, the intervention was compared to common practice where guidelines are developed and disseminated with no accompanying training and/or follow-up supervision. DALYs were calculated using standard methods [@pmed.1001238-FoxRushby1]. DALYs are generic measures of health outcomes derived by adding the years of life lost due to disease (YLL) and the years of life lived with disability (YLD) [@pmed.1001238-FoxRushby1]--[@pmed.1001238-Anand1]. DALYs were calculated using a discount rate of 3%, age weighting and disability weights for malaria episode (0.19), lower respiratory infection episode (0.28), and diarrheal diseases (0.11) [@pmed.1001238-Lopez1]. Separate DALY calculations for each of these diseases where made and summed up to yield total DALYs averted by the intervention.

Total Costs of Scale-up {#s2k}
-----------------------

Kenya has 121 hospital facilities with estimated median annual pediatric admissions of 2,000 per facility across this group, representing a total for pediatric admissions of 242,000 per annum (there are a larger number of smaller hospitals not considered in this analysis). We estimated the cost of scaling up this intervention with a number of assumptions: (1) Development costs do not vary with scale-up; given that they are only incurred once, they are not a function of the scale of the intervention; (2) That training, supervision, and follow-up costs (implementation) vary as a function of the number of hospitals; (3) That treatment costs vary as a function of the number of pediatric admissions; (4)That the intervention would reach all 121 hospitals when at scale. It is however difficult to estimate potential economies of scale and scope, for example for supervision, that might lessen costs or specific, higher, travel costs for hard to reach areas during scale up. Given the skewness of treatment costs, their scale-up component costs were calculated on the log-scale and then back transformed to the original scale.

Sensitivity Analysis {#s2l}
--------------------

Uncertainty was addressed by specifying distributions around cost and effectiveness parameters and conducting probabilistic sensitivity analysis using Crystal Ball software (Decisioneering). Triangular distributions with plausible ranges were fitted around the effectiveness estimate, development costs, salaries, medicines, and "hotel" components of costs ([Table 1](#pmed-1001238-t001){ref-type="table"}). Intervention effectiveness was varied to reflect the range of process of care improvements between intervention and control hospitals across the 14 indicators; from 3.54%, to 52.10%, the smallest and greatest reported difference between control and intervention hospitals\' indicators. Development costs were varied to reflect a scenario where a "ready made" intervention was adopted hence having zero intervention costs, and a scenario where the full development costs were incurred. The "hotel" unit cost estimate used in the base case, which was also used to compute the lower range in the sensitivity analysis, was the WHO-CHOICE estimate for district hospitals in Kenya, inflated to 2009 (US\$6.96 per day) [@pmed.1001238-WHO1], while the upper range was computed from an estimate from a Kenyan study inflated to 2009 (US\$15.05 per day) [@pmed.1001238-Nganda1]. The lower range of salary costs was derived by assuming the intervention implementers were compensated at government of Kenya salary scales while the upper limit, which was also the estimate used in base case, assumed that intervention implementers were compensated at the salary scales of the research organization that implemented the intervention. The range of medicine costs was derived from variations in market prices in the 2010 Kenya drug prices catalogue. Confidence intervals around the mean ICER were derived from 1,000 Monte Carlo simulations.

10.1371/journal.pmed.1001238.t001

###### Parameter ranges and distributions.

![](pmed.1001238.t001){#pmed-1001238-t001-1}

  Parameter (Costs per Child Admission)     Base Case (US\$)   Range (US\$)   Distribution
  ---------------------------------------- ------------------ -------------- --------------
  Full intervention development costs             8.11           0--8.11       Triangular
  Partial intervention development costs          4.95           0--4.95       Triangular
  Full intervention salary costs                 12.46         11.42--12.46    Triangular
  Full intervention hotel costs                  20.68         20.68--39.93    Triangular
  Full intervention medicine costs                2.30          0.66--8.06     Triangular
  Partial Intervention salary costs               3.65          1.67--3.65     Triangular
  Partial intervention hotel costs               20.15         20.15--38.89    Triangular
  Partial intervention medicine costs             1.74          0.50--6.09     Triangular
  Intervention Effectiveness                     25.01         3.54--52.10     Triangular

Results {#s3}
=======

Changes in Process of Care Measures {#s3a}
-----------------------------------

The mean of the adjusted differences of the 14 process measures between control and intervention hospitals was 25.01% (95% CI 17.87%--32.18%). The findings of performance changes across all process measures in both control and intervention hospitals are presented in [Table 2](#pmed-1001238-t002){ref-type="table"}.

10.1371/journal.pmed.1001238.t002

###### Average performance in control and intervention hospitals at baseline and 18 mo follow-up and adjusted difference (95% CI) at 18 mo.

![](pmed.1001238.t002){#pmed-1001238-t002-2}

  Indicator of Quality of Care                                                     Intervention   Control   Adjusted Difference between Groups at 18 mo (%)[a](#nt101){ref-type="table-fn"}   95% CI                       
  ------------------------------------------------------------------------------- -------------- --------- --------------------------------------------------------------------------------- -------- ----------- -------- -------
  **Process indicators**                                                                                                                                                                                                   
  **Child\'s weight documented**                                                      59.30        84.50                                         21.00                                        63.20      22.80     −4.05    49.70
  **Child\'s temperature documented**                                                 11.90        71.90                                         25.10                                        46.60      26.50     −4.49    57.50
  **Average assessment score**                                                        24.00        94.00                                         32.00                                        65.00      29.00      5.00    54.00
  **Proportion of pneumonia episodes with a severity classification**                  9.29        95.10                                         14.70                                        57.00      38.57      9.87    67.30
  **Proportion of gentamicin prescriptions with once daily dose**                      1.85        89.20                                         3.54                                         74.40      17.05      8.04    26.10
  **Proportion of gentamicin prescriptions with daily dose \<4 mg/kg**                24.90        2.16                                          23.40                                         8.99      6.77      −11.90   −1.59
  **Proportion of gentamicin prescriptions with daily dose** **≥10 mg** **/kg**        3.78        6.25                                          7.15                                          9.82      3.54      −11.10   4.00
  **Proportion with adequate oxygen prescriptions**                                    0.00        37.00                                         0.00                                          2.31      35.10      7.32    62.80
  **Proportion of malaria episodes with a severity classification**                   10.10        92.50                                         2.48                                         41.10      52.10     26.20    78.00
  **Proportion of severe malaria with quinine loading**                                4.20        91.90                                         14.80                                        66.70      26.30     −3.66    56.30
  **Proportion of severe malaria with twice daily quinine maintenance dose**           0.39        87.80                                         9.95                                         45.70      42.60     25.10    60.20
  **Proportion of severe malaria with quinine daily dose** ≥**40 mg/kg**               7.33        1.02                                          14.10                                         7.46      6.53      −12.90   −0.20
  **Proportion of dehydration episodes with a severity classification**               52.40        98.30                                         60.50                                        84.80      14.40      4.27    24.60
  **Correct intravenous fluid prescription**                                           7.32        67.20                                         15.00                                        40.60      29.90     10.90    48.90
  **Mean change in quality of care**                                                  13.79        58.98                                         15.15                                        39.24    **25.01**   17.87    32.18

Adjusted difference between intervention arms obtained from linear or logistic regression analysis of hospital summary data adjusting for child\'s sex and hospital factors (size, malaria endemicity, HIV prevalence, all cause mortality).

Intervention Costs {#s3b}
------------------

Total intervention costs and admission costs per child in intervention and control hospitals are presented in [Table 3](#pmed-1001238-t003){ref-type="table"}. An average of 32 health workers underwent the initial ETAT+ training at a cost of US\$8,069.32 per intervention hospital or US\$252.16 per trainee. Follow-up training, supervision, and local facilitator costs were 19.89% of total intervention costs in intervention hospitals. The annual costs of a local facilitator per facility were US\$5,697.87, 5.62% of total intervention costs in intervention hospitals.

10.1371/journal.pmed.1001238.t003

###### Summary of intervention costs.

![](pmed.1001238.t003){#pmed-1001238-t003-3}

  Cost Items                         Intervention Hospitals           Control Hospitals   As Percent of Total Intervention Costs          
  --------------------------------- ------------------------ ------- ------------------- ---------------------------------------- ------- -------
  **Guideline development costs**                                                                                                         
  Development costs                        16,227.46          8.11          15.98                        9,898.29                  4.95    15.93
  Training material costs                    692.92           0.35          0.69                           0.00                    0.00    0.00
  **Total start-up costs**                 16,920.39          8.46          16.67                        9,898.29                  4.95    15.93
  **Implementation costs**                                                                                                                
  Initial training                          8,069.32          4.03          7.94                         2,017.33                  1.01    3.25
  **Follow-up activities**                                                                                                                
  Follow-up trainings                       4,348.05          2.17          4.28                           0.00                    0.00    0.00
  Local facilitator costs                   5,697.87          2.85          5.62                           0.00                    0.00    0.00
  Supervision costs                        10,135.50          5.07          9.99                           0.00                    0.00    0.00
  **Total follow-up costs**                20,181.42          10.09         19.89                          0.00                    0.00    0.00
  **Total implementation costs**           28,250.73          14.13         27.85                        2,017.33                  1.01    3.25
  **Start-up and implementation**          45,171.11          22.59         44.52                       11,915.62                  5.96    19.19
  **Treatment costs**                                                                                                                     
  **Hotel costs**                            45,080           22.54         44.42                         41,800                   20.90   67.28
  **Drug costs**                             5,080            2.51          4.95                          3,600                    1.80    5.80
  **Lab costs**                              11,260           5.63          11.10                         6,660                    3.33    10.72
  **Total treatment cost**                 56,304.79          28.15         55.48                       50,202.30                  25.10   80.81
  **Total costs**                          101,475.90         50.74          ---                        62,117.92                  31.06    ---

Obtained by dividing the total cost per hospital by the estimated number of annual admissions for children under five per hospital (2,000).

Treatment Costs {#s3c}
---------------

An ordinary linear (OLS) regression of (log transformed) treatment costs revealed that costs did not significantly vary with child diagnosis, hospital, and time (i.e., across the four surveys) (unpublished data). We therefore pooled treatment costs across surveys and diagnoses within each study arm to increase sample sizes. The mean and median treatment costs were US\$28.15 (95% CI 27.61--28.70) and US\$22.47 (interquartile range \[IQR\] 14.33--32.78), respectively, in intervention hospitals and US\$25.10 (95% CI 24.56--25.65) and US\$19.25 (IQR 13.01--29.04) in control hospitals. "Hotel" costs were the key driver of treatment costs and contributed between 73.18% and 79.98% of treatment costs. Treatment costs disaggregated by category are presented in [Table S1](#pmed.1001238.s002){ref-type="supplementary-material"}, while treatment costs per admission episode are presented in [Table S2](#pmed.1001238.s003){ref-type="supplementary-material"}.

Incremental Costs, Effects, and Cost-Effectiveness Analysis {#s3d}
-----------------------------------------------------------

The incremental cost per admission in intervention hospitals compared to control hospitals was US\$19.68 (95% CI 5.31--31.92). The incremental cost per percentage improvement in quality of care was US\$0.79 (95% CI 0.19--2.31) per child admission. These results are presented in [Table 4](#pmed-1001238-t004){ref-type="table"}.

10.1371/journal.pmed.1001238.t004

###### Cost-effectiveness analysis.

![](pmed.1001238.t004){#pmed-1001238-t004-4}

  Strategy                    Mean Admission Costs per Child US\$ (95% CI)   Incremental Cost US\$ (95% CI)   Incremental Effects (Percent Change in Quality of Care) (95% CI)     ICER (95% CI)
  -------------------------- ---------------------------------------------- -------------------------------- ------------------------------------------------------------------ -------------------
  **Partial intervention**                31.06 (30.67--47.18)                            ---                                               ---                                         ---
  **Full Intervention**                   50.74 (49.26--67.06)                    19.68 (5.31--31.92)                              25.01% (17.87--32.18)                         0.79 (0.19--2.31)

Estimated Costs of Scale-up and Budget Impact {#s3e}
---------------------------------------------

For an estimated coverage of 121 district hospitals and 242,000 annual under-five admissions, the estimated costs of scale-up were found to be US\$3,559,328.78. This amount is estimated to be equivalent to 0.60% of the estimated 2010 annual budget for formal provision of care to children under five in Kenya ([Table 5](#pmed-1001238-t005){ref-type="table"}).

10.1371/journal.pmed.1001238.t005

###### Total costs of scale-up.

![](pmed.1001238.t005){#pmed-1001238-t005-5}

  Description                                                                                                       Full Intervention US\$   Partial Intervention US\$
  ---------------------------------------------------------------------------------------------------------------- ------------------------ ---------------------------
  ***n*** **district hospitals**                                                                                             121                        121
  **Estimated annual pediatric admission to district hospitals in Kenya**                                                  242,000                    242,000
  **Costs of national scale-up**                                                                                          3559328.78                 271386.32
  **Budget for provision of under-five child health services in Kenya in 2010** [a](#nt103){ref-type="table-fn"}         572,000,000                572,000,000
  **Impact of scaling up ETAT+ on the annual child health budget**                                                          0.60%                      0.06%

Estimates of annual budget (2010) for provision of care to children under five derived from the Kenya national health sector strategic plan 2 (NHSSP II).

Incremental Cost per DALY Estimates Given Probable Reductions in Mortality {#s3f}
--------------------------------------------------------------------------

The mean baseline inpatient child mortality rate in the eight hospitals was 7% [@pmed.1001238-Ayieko1]. Assuming the intervention produces a 1%--10% relative reduction in this mortality rate (absolute reductions between 0.07% and 0.7%), the incremental cost per DALY averted would range between US\$398.3 and US\$39.8, respectively. [Figure 1](#pmed-1001238-g001){ref-type="fig"} explores the relationship between reduction in mortality and intervention cost effectiveness at different baseline mortality rates while [Table 6](#pmed-1001238-t006){ref-type="table"} compares the range of potential ICERs with those from other key child health interventions that are considered cost effective.

![Relationship between reductions in inpatient mortality and the incremental cost per DALY averted.](pmed.1001238.g001){#pmed-1001238-g001}

10.1371/journal.pmed.1001238.t006

###### Cost per DALY averted estimates of comparable child health interventions.

![](pmed.1001238.t006){#pmed-1001238-t006-6}

  Child Health Intervention                                                                                                      Incremental Cost per DALY Averted US\$[a](#nt104){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  Expanded immunization programme [@pmed.1001238-Laxminarayan1]                                                                                                13.0--26.1
  Hemophilus Influenzae vaccine (Hib) [@pmed.1001238-Akumu1]                                                                                                   32.4--78.6
  Provision of insecticide treated nets (ITNs) [@pmed.1001238-Goodman1]                                                                                       34.6--154.8
  Improving inpatient care of very sick children (assuming between 10% and 1% reduction in baseline inpatient mortality rate)                                 39.8--398.3
  Integrated Management of Childhood Illnesses (IMCI) [@pmed.1001238-Victora1]                                                                                47.1--157.1
  Pneumococcal conjugate vaccine [@pmed.1001238-Sinha1]                                                                                                       71.1--230.7
  Oral rehydration therapy (ORT) [@pmed.1001238-Laxminarayan1]                                                                                               172.2--3352.0
  Measles immunization [@pmed.1001238-Laxminarayan1]                                                                                                         335.2--5954.1
  Breast feeding promotion programmes [@pmed.1001238-Laxminarayan1]                                                                                          687.4--2609.9

ICER values adjusted to 2009 values using GDP deflators.

Sensitivity Analysis {#s3g}
--------------------

The incremental cost-effectiveness ratios were robust to changes in most of the variables included in the sensitivity analysis. Four factors (intervention effectiveness, hotel costs, medicine costs, and staff salaries) contributed 99% of the total variance in the ICER ([Figure 2](#pmed-1001238-g002){ref-type="fig"}). The major contributors to this variance were intervention effectiveness (49%) and hotel costs (43%). Salary and medicine costs contributed to 4% of ICER variance each, while development costs contributed 1% of the variation. The higher the intervention effectiveness, the lower the ICER (increased intervention cost effectiveness), while the higher the costs (hotel, salary, medicine, development costs) the higher the ICER (reduced intervention cost effectiveness).

![Parameter contribution to ICER variance.](pmed.1001238.g002){#pmed-1001238-g002}

Discussion {#s4}
==========

This analysis compares the costs and effects of a guideline-based intervention aimed at improving the quality of care of children admitted to district hospitals in Kenya. In analyzing the costs, we included the costs of developing clinical guidelines that are often left out in such analyses [@pmed.1001238-Grimshaw1]. Our analysis revealed that these costs formed 16% of the overall intervention costs, suggesting that this component is an important cost driver that should not be ignored. The development costs are however minimal at scale-up, given that they are incurred once and do not vary with the scale of the intervention. The average training cost per health worker was US\$252.16, which is significantly lower than training costs for similar interventions such as Integrated Management of Childhood Illness (IMCI) where the reported median cost was US\$633 [@pmed.1001238-Rowe1]. One of the unique components of this intervention was the appointment of a local facilitator in intervention hospitals. The annual cost of this facilitator per facility was US\$5,698. The local facilitator worked at the facility for the entire intervention period. This provided continuity and helped to keep the "quality agenda" on the table [@pmed.1001238-English3].

There are many challenges in undertaking cost-effectiveness analyses of interventions targeting hospitals and multiple diseases. Basic challenges include the lack of high quality data on hotel costs. These represent between 73% and 80% of total treatment costs for children admitted with common diseases even though inpatient stays are typically 3 d or less. We used the WHO-CHOICE hotel cost estimates applicable to district hospitals in Kenya. In effect, the use of these data amounts to an assumption that there are no major differences in the intensity of staffing per patient. While this assumption was justified as we did not expect that our intervention would require different levels of health worker input within the different hospital settings, we acknowledge that poor primary data is a potential shortcoming and suggest that addressing this information gap is a priority.

Specifying summary measures that capture intervention effects is also a challenge [@pmed.1001238-Barasa1]. We used a mean percentage improvement in quality assessed across 14 indicators for the three major causes of admission and inpatient death in children [@pmed.1001238-Ayieko1]. By this measure, intervention hospitals outperformed control hospitals by 25%. However, such a measure gives equal weight to each indicator, with which some might disagree. This assumption is, however, consistent with findings from an international Delphi study conducted with pediatric experts where the respondents rated these 14 process of care indicators as having similar priority for improvement [@pmed.1001238-Ntoburi1]. It can be argued however that certain process measures, for example those targeting appropriate dosing of medicines, are more important than others, such as processes that target patient assessment. Despite the lack of an agreed weighting for these processes, we explored a weighting procedure (unpublished data) that gives higher weight to treatment processes (weight 3), followed by diagnosis processes (weight 2), and lastly assessment processes (weight 1). The resultant effect size (24.0%) was not significantly different from the unweighted estimate (25.01%) and fell within the range used in the sensitivity analysis. The effectiveness measure also fails to capture potentially important additional improvements resulting from intervention, for example improved organization of care, better local resource mobilization [@pmed.1001238-Ayieko1], more rational use of antibiotics [@pmed.1001238-Opondo1], and positive effects on staff morale [@pmed.1001238-Nzinga1]. Conversely the measure does not capture potential declines in quality in other areas that are not the focus of intervention. Methodological research is thus needed to optimize effect measures for complex interventions targeting improvements in hospital care for multiple diseases.

While acknowledging these limitations our findings suggest an additional cost of US\$0.79 per child admitted to achieve a one percentage point improvement in this summary quality measure. The probabilistic sensitivity analysis reveals that hotel costs and intervention effectiveness contributed to more than 80% of the variation in this ICER. This finding has two implications: (1) The sensitivity analysis underlines the effects of poor data on hotel costs and methodological deficiencies in computing a summary measure of quality improvement; (2) Hotel costs (being key drivers of treatment costs) and intervention effectiveness have a significant impact on the cost effectiveness of this quality of care intervention.

Translating improvements in process measures into improved health status outcomes is problematic and the cluster randomized trial was not designed to measure effects on inpatient child mortality [@pmed.1001238-English4]. However, to provide some means to consider the potential value of the intervention in terms of incremental cost per DALY averted and life years gained, we conducted a simple "what-if" analysis. We considered a reasonably conservative range of relative reductions in baseline mortality of between 1% and 10%, absolute reductions of mortality of 0.7% to 0.07% from a baseline of 7%. This range of mortality reductions is considered conservative when compared to findings suggesting improved case management for common childhood diseases in primary care may result in mortality reduction of 13% in Tanzania [@pmed.1001238-Schellenberg1]. Also, evaluations of quality improvement and safety programmes in developed countries have reported mortality reductions of between 5% and 51% [@pmed.1001238-Haraden1]--[@pmed.1001238-Pronovost1]. The implication is that the cost effectiveness of the interventions is likely to be more favorable than we have suggested. The findings suggest that the incremental cost per DALY averted from scaling up the intervention would vary from US\$39.8 to US\$398.3. These ICERs compare favorably with other key public health interventions to reduce child mortality considered to be cost effective such as provision of insecticide treated bed nets (US\$34.60--US\$154.8 per DALY averted) [@pmed.1001238-Goodman1] or oral rehydration therapy (ORT) (US\$172.2--US\$3352.0 per DALY averted) [@pmed.1001238-Laxminarayan1]. The intervention is likely most cost effective when hospital mortality is high ([Figure 1](#pmed-1001238-g001){ref-type="fig"}) and baseline quality of care poor. Such analyses raise the question of whether quality improvement should be targeted at high mortality hospitals. While such simple modeling approaches suggest improving the quality of rural hospital care may be highly cost effective, demonstrating such small reductions in mortality in a randomized controlled trial would be extremely difficult. For example, demonstrating an absolute, inpatient mortality reduction of 0.5% from a baseline of 7% in a typical cluster randomized trial, using conventional values for statistical significance and power, would likely require all 121 Kenyan hospitals to be enrolled, randomized, and evaluated over 1 y [@pmed.1001238-Hayes1]. The costs of such a trial would be prohibitively high and would amount to scaling up anyway.

Often the feasibility of scaling up is determined by likely costs. For the multifaceted intervention employed these were estimated to be US\$3,559,328 if conducted by non-government personnel and 27% less if by government personnel. This amount can be compared with average annual projected expenditures by the Kenyan government on all care for children under five of US\$572 million [@pmed.1001238-MOH1] and on other specific health projects such as the distribution of insecticide treated nets (US\$8 million) and prevention of mother to child transmission of HIV (US\$6 million) [@pmed.1001238-MOMS1]. While the costs of scale-up might be small (approximately 0.6% of the child health budget), scaling up the ETAT+ intervention nationally would either require the child health budget to be increased or that allocation to other areas be reduced by an equivalent amount.

Cost-effectiveness and affordability data are, however, not the only factors that should inform such allocative decisions. Other important considerations may include, equity, likely collateral benefits or adverse effects, and, of course, context and the politics of the day. Unfortunately methods to support and make transparent such complex prioritization decisions remain poorly developed. Advantages of scaling up such an integrated package of interventions encompassed in the ETAT+ strategy include potentially important externalities related to more general health system strengthening and introduction of a culture of improvement [@pmed.1001238-Ayieko1],[@pmed.1001238-English3]. For those in other settings reviewing these results, it should be clear that the greatest apparent cost effectiveness is likely to occur in settings providing, reliably, a minimum set of basic resources but where quality of care, in terms of process, is poor and mortality high. Findings from this work are therefore likely to be generalizable to low-income countries with similar public hospital characteristics, child burden of disease, and comparable quality of delivery of pediatric care as found in hospitals at baseline in Kenya.

Our work adds to a very small body of literature on economic evaluation of quality of care interventions [@pmed.1001238-Vale1]. The few that are available from low-income settings, including evaluations of Integrated Management of Childhood Illness (IMCI), adopted a similar approach [@pmed.1001238-Schellenberg1],[@pmed.1001238-Bishai1],[@pmed.1001238-Bryce1]. A major limitation of these approaches is that they fail to fully elucidate the value of the intervention to the patients, health workers, and organizations, and by extension to decision makers. Further, because effect measures are unique to the interventions it is not possible to compare results directly with other cost-effectiveness or cost-utility studies. To provide a more explicit framework for comparison requires modeling the link between process measures of improved quality and health outcomes, which would be complex and likely based largely on expert opinion. As an alternative we used an approach that explored potentially plausible overall effects on hospital mortality. This can clearly be challenged but is mainly used for illustration. In the absence of data on mortality effects perhaps a method of valuing quality improvement interventions that encompasses more than health outcomes might be more appropriate and could reflect utility by, for example, eliciting society\'s preferences.

Conclusion {#s4a}
----------

This analysis has shown that the improvement in quality of care attributed to the ETAT+ strategy (7) is associated with additional costs that are affordable to low-income countries like Kenya. The intervention may be relatively cost effective compared with standard care if the improvements observed are associated with reasonably conservative reductions in inpatient child mortality. The absolute costs for scaling up are comparable to or lower than costs of other, major child health interventions. As increasing focus is being given to strengthening health systems there would therefore appear to be a reasonably strong case for scaling up this intervention that improves service provision in rural hospitals for the major causes of child mortality in Kenya. This work also highlights the need for methodological developments in the economic analysis of complex, system-level interventions. These results are likely to be most usefully generalized to low-income countries beyond Kenya with similar facilities, burden of child mortality, and comparable or worse quality of pediatric care in hospitals.
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